Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduning Injection for Chikungunya Fever
NCT07126171Not yet recruiting
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Nov 2025
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Randomised, double-blind trial in chikungunya fever (CHIKV) comparing Reduning treatment group with placebo group (2 arms). Primary endpoint: Duration of symptoms up to 90 days. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
Reduning
03
Conditions
chikungunya fever (CHIKV)
Beyond the preview
Go deeper on NCT07126171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126171.